Par Pharmaceutical Receives Final Approval To Market Tretinoin Capsules

Par Pharmaceutical Companies, Inc. today announced that its operating subsidiary, Anchen Pharmaceuticals, Inc., has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for tretinoin capsules, 10 mg.  Tretinoin capsules is the generic version of Vesanoid^® capsules and is used in the treatment of acute promyelocytic leukemia.  Par expects to begin shipping the product before the end of the month.